Presentation is loading. Please wait.

Presentation is loading. Please wait.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Published byHolly Johnson Modified over 5 years ago

Similar presentations

Presentation on theme: "Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the."— Presentation transcript:

1 Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the Lung  Martin Frederik Dietrich, MD, PhD, Shirley Xiao Yan, MD, Joan Hoff Schiller, MD  Journal of Thoracic Oncology  Volume 10, Issue 5, Pages e23-e25 (May 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Radiographic evaluation of left lower lobe (LLL) (upper series) and right upper lobe (RUL) (lower series). The lesions that have taken for biopsy are marked by arrows. The timeline refers to time since initial diagnosis of LLL lesion. The upper series demonstrates continuous shrinkage after initiation of erlotinib. The patchy infiltrates at 7 months are biopsy proven to be bronchiolitis obliterans organizing pneumonia. The lower series demonstrates an RUL lesion with interval growth between baseline and 5 months, followed by significant shrinkage after initiation of crizotinib. *The 2-week time frame of drug discontinuation due to transaminitis. Journal of Thoracic Oncology  , e23-e25DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Morphologic features and immunohistochemical stains for left lower lobe (LLL) (A–C) and right upper lobe (RUL) (D–F) tumors. Hematoxylin and eosin stains for LLL (A) and RUL (D). Positive TTF-1 stains in LLL (B) and RUL (E). Positive napsin A staining in LLL (C) and negative staining in RUL (F). Journal of Thoracic Oncology  , e23-e25DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Avoidance of completion pneumonectomy by sparing the right middle lobe

Avoidance of completion pneumonectomy by sparing the right middle lobe
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
Sclerosing Pneumocytoma with Lymph Node Metastasis

Sclerosing Pneumocytoma with Lymph Node Metastasis
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD 

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD 
Difference in Clonality as a Tool for Differential Diagnosis of Primary Versus Secondary Lung Neoplasms  Giovanni Leuzzi, MD, Alfredo Cesario, MD, Maria.

Difference in Clonality as a Tool for Differential Diagnosis of Primary Versus Secondary Lung Neoplasms  Giovanni Leuzzi, MD, Alfredo Cesario, MD, Maria.

Similar presentations

Ads by Google